API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Balixafortide (POL6326), is a potent, specific and highly selective macrocycle inhibitor of CXCR4 that plays a role in a number of tumor types as well as non-oncology indications.
Lead Product(s): Balixafortide,Undisclosed
Therapeutic Area: Oncology Product Name: POL6326
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
In this trial, POL6326 (balixafortide) was shown to be safe and well tolerated in all subjects, with only transient and mild-to-moderate manageable hypersensitivity-like events known to occur during initial drug infusion with CXCR4 inhibitors.
Lead Product(s): Balixafortide
Therapeutic Area: Nephrology Product Name: POL6326
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2022
Details:
The preclinical study of metastatic prostate cancer combining POL6326 (balixafortide) and docetaxel (5 mg/kg once weekly) assessed tumor burden and tumor-induced bone degradation. Overall, results showed superior synergistic efficacy compared to either drug alone.
Lead Product(s): Balixafortide,Docetaxel
Therapeutic Area: Oncology Product Name: POL6326
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: University of Michigan
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Details:
Balixafortide (POL6326) is a potent, specific, and highly selective antagonist of the chemokine receptor CXCR4, a G-protein coupled receptor (GPCR) that regulates the trafficking and homing of both cancer cells and cells of the patient’s immune system.
Lead Product(s): Balixafortide,Eribulin
Therapeutic Area: Oncology Product Name: POL6326
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2021
Details:
The study confirmed the positive safety and tolerability profile of balixafortide in line with the previously reported Phase Ib study.
Lead Product(s): Balixafortide,Eribulin
Therapeutic Area: Oncology Product Name: POL6326
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2021
Details:
Balixafortide is a potent, selective CXCR4 antagonist which is currently also in Phase III development in combination with eribulin in patients with metastatic HER-2 negative breast cancer.
Lead Product(s): Balixafortide
Therapeutic Area: Infections and Infectious Diseases Product Name: POL6326
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2021
Details:
The FORTRESS study is an international, multicenter, randomized active-controlled, open-label Phase III trial which investigates the efficacy, safety and tolerability of intravenous balixafortide given with eribulin vs eribulin alone to treat metastatic breast cancer.
Lead Product(s): Balixafortide,Eribulin
Therapeutic Area: Oncology Product Name: POL6326
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
If successful, balixafortide will be the first in class CXCR4 antagonist approved for a solid tumor indication widening the opportunities in the field of immuno-oncology.
Lead Product(s): Balixafortide,Eribulin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2020